A 2026 guideline on the management of dyslipidemia expands recommendations for primary prevention statin therapy among the US population.

The FDA has approved Simtriyo (centanafadine), a first-in-class NDSRI and CNS stimulant, for adult and pediatric ADHD aged 6 years and older.

Perampanel offers meaningful seizure control and an acceptable safety profile for patients with brain tumor-related epilepsy, a new review shows.

An outside advisory panel to the FDA is pushing for the production and sale of a few previously banned peptide treatments.

FDA accepts the resubmitted NDA for SL1009 (sodium dichloroacetate) to treat pyruvate dehydrogenase complex deficiency.

Many adults born with a very low birth weight or very preterm exhibit lower positive functioning in early adulthood.

Better cardiovascular health during pregnancy is associated with longer time to incident postdelivery diagnosis of cardiometabolic conditions.

Melatonin may offer modest pain relief and improved sleep for patients with chronic musculoskeletal pain, but it lacks benefit for postoperative pain.

An emergency presentation for a cancer diagnosis is common and predicts persistently elevated mortality among older US adults.

Molecular profiling, biomarker detection, and in vivo imaging are reshaping how neurologists diagnose neurodegenerative ...

Despite questions about safety and regulation, there is still a strong market for compounded GLP-1 RA alternatives.

The Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593 for the treatment of narcolepsy. Narcolepsy type 1 is a rare neurological condition caused ...